The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Xin, Shuang, Zhao, Yuanyuan, Wang, Xueding, Huang, Yan, Zhang, Jing, Guo, Ying, Li, Jiali, Li, Hongliang, Ma, Yuxiang, Chen, Lingyan, Hu, Zhihuang, Huang, Min, Zhang, Li
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/
https://ncbi.nlm.nih.gov/pubmed/26228025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky